Project Grant R43GM159530
- This $314,000 Project Grant was awarded on September 1, 2025 by the National Institute of General Medical Sciences (NIGMS), which administers the Biomedical Research and Research Training program (CFDA 93.859). The grant was awarded to Cellfe, Inc. to optimize their CellFE microfluidic transfection platform for accelerated, scalable same-day sequential gene editing of T cells for allogeneic cell therapies. The project aims to enhance the speed, precision, and scalability of CRISPR-based gene...
- This $316,825 Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to advance the field of native mass spectrometry (MS) analysis. The research project will develop an innovative intact mass deconvolution method to significantly improve the speed, accuracy, and user-friendliness of proteins and nucleic acid molecular weight determination using MS. The key objectives are to implement...
- This federal Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop an affordable platform for rapid, high-resolution, single-cell analysis of the identity of human-induced pluripotent stem cells (hiPSCs). The platform will leverage technologies such as microscopic imaging of the epigenetic landscape, picowell arrays, and fluidic devices to enable affordable,...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development of a novel in-line biomanufacturing process analytical technology tool. The $302,417 award to Physical Sciences Inc. (PSI), in collaboration with the University of Massachusetts Lowell (UML), aims to enable real-time monitoring of biomolecules in large-scale bioreactors for gene therapy manufacturing. The technology...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA program 93.859 Biomedical Research and Research Training provides $350,000 to Fluidispec LLC to develop a new microfluidic/nanofluidic sample preparation platform. The goal is to improve single-cell and low-input proteomics analysis by enabling efficient extraction of proteins from cells, removal of contaminants, and improved protein denaturation. This platform is expected to enhance...
- The federal Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) is supporting the development and demonstration of a novel enzyme-based, single-molecule protein sequencing system by Electronic Biosciences, Inc. This innovative platform leverages enzyme-driven processing and sequencing of individual proteins and peptides, combined with advanced bioinformatics, to achieve high...
- This Project Grant award for $450,904 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a single-cell (phospho-)proteomics platform at the Pacific Northwest National Laboratory, operated by Battelle Memorial Institute. The platform aims to address key challenges in single-cell proteomics analysis, including low recovery for phospho-enrichment, insufficient mass spectrometry sensitivity, and low sample throughput. This new platform will...
- This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
- This federal Project Grant award of $427,625 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop capillaric microfluidics for integrated sample preparation in miniaturized mass spectrometry (mini-MS) systems. The research will focus on creating portable, self-powered, and self-regulated sample preparation capabilities to improve the versatility and applicability of mini-MS instruments for...
- This federal Project Grant award for $390,000.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports the development of new tools for high-throughput characterization of extracellular RNA, DNA, and vesicles in bodily fluids. The primary objectives are to: 1) develop methods to reliably control for technical variability, RNA degradation, and complexity in cell-free RNA (cfRNA) analysis, including...
This $302,671 federal Project Grant awarded on August 2, 2025 by the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) to Andson Biotech Inc. aims to develop an innovative real-time mass spectrometry platform for in-process monitoring and cell state analysis of advanced cell therapies. The project seeks to address the challenges of variable quality and efficacy in cell therapies by enabling real-time measurement and control of critical process parameters and quality attributes. The proposed platform leverages mass spectrometry's sensitivity and multi-analyte capabilities to provide deeper, temporal insights into the biological processes underlying cell therapy manufacturing and patient-specific responses. By enhancing process analytical technology (PAT) capabilities, this project aims to facilitate in-process adjustments and improve understanding of final product quality and patient efficacy, ultimately advancing the development of more consistent and effective biotherapeutics.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $302.7k | 7/31/25 |